Janux Therapeutics, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; this 10-K reports annual results, not standalone fourth-quarter results. The financial statements were audited by Ernst & Young LLP, which issued an unqualified opinion.
Business context
Janux is a preclinical-stage biopharmaceutical company developing cancer immunotherapies using its TRACTr and TRACIr platforms. Its lead programs target PSMA, EGFR and TROP2; a PD-L1xCD28 TRACIr candidate was selected in Q4 2021. No candidate had entered clinical trials, and the company had no approved products or product-sale revenue.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Collaboration revenue | $3.6 million | None |
| Research and development expense | $26.2 million | $3.0 million |
| General and administrative expense | $10.3 million | $1.8 million |
| Net loss | $32.7 million | $6.8 million |
| Net loss per share, basic and diluted | $1.39 | $7.41 |
| Net cash used in operating activities | $17.0 million | $4.4 million |
- Revenue was from the Merck research collaboration; Janux generated no product revenue. Operating expenses substantially exceeded revenue, so operating and profit margins were negative; profitability is not established.
- R&D expense rose $23.2 million, mainly from platform and program development ($15.5 million), personnel and facilities ($4.0 million), and stock-based compensation ($3.0 million). G&A rose $8.5 million, including higher stock-based compensation, personnel/facilities and public-company costs.
- At year-end, cash and cash equivalents were $35.6 million, short-term investments $339.4 million, and restricted cash $0.8 million. Total assets were $379.8 million; total liabilities were $13.5 million. Current assets were $377.0 million versus current liabilities of $12.8 million.
- No outstanding debt was reported at December 31, 2021. The company reported an accumulated deficit of $47.4 million and stockholders’ equity of $366.3 million.
- Cash provided by financing was $386.5 million, including $204.2 million net IPO proceeds and $180.5 million net proceeds from Series A and B preferred stock sales. Investing activities used $341.0 million, primarily for net purchases of short-term investments.
Material changes and outlook
- Janux completed its IPO in June 2021, selling 13.11 million shares at $17 per share. Preferred shares converted to common stock in the offering.
- Management said available cash and short-term investments should fund operations and capital needs for at least 12 months after the report date, but would not fund candidates through regulatory approval. Additional capital will likely be needed; no profitability or revenue guidance was provided.
- Management planned to submit an IND for PSMA-TRACTr in the first half of 2022, EGFR-TRACTr in the second half of 2022, and TROP2-TRACTr and PD-L1xCD28-TRACIr in 2023. These were targets, not achieved milestones; all programs remained preclinical or in discovery at year-end.
- Janux reported preclinical and non-human-primate findings it believes may support reduced CRS and healthy-tissue toxicity and longer half-lives. These findings do not establish safety, efficacy, dosing or clinical benefit in humans.
- The Merck agreement provides research funding and potential upfront, milestone and royalty payments. One target was selected; a second could be selected for an additional $8 million. Development/regulatory milestones are capped at $142.5 million per target, and commercial milestones at up to $350 million per licensed product, plus tiered royalties. These amounts are contingent, not guaranteed revenue.
- The company reported $37.7 million of estimated undiscounted payments over the 126-month term of its planned office/laboratory lease, expected to commence in July 2022. A separate office lease had $0.2 million of remaining 2022 minimum payments at year-end.
Risks, contingencies and notable items
- Janux has a short operating history, recurring losses and no human clinical-trial experience. Preclinical results may not predict clinical outcomes, and candidates may fail, be delayed or require substantial additional investment.
- Clinical development, manufacturing and supply depend substantially on third parties; the company reported reliance on a single-source contract manufacturer for bulk drug substance. COVID-19, enrollment, regulatory review, competition and supply disruption may affect timelines and costs.
- Other significant risks include toxicity, regulatory approval, intellectual-property protection and infringement, financing and dilution, reimbursement and market acceptance, key-personnel retention, data privacy/cybersecurity, and dependence on Merck for collaboration-related potential revenues.
- No material legal proceedings were reported. Management concluded disclosure controls were effective at a reasonable-assurance level; the company did not provide an auditor attestation on internal control over financial reporting because it was not required during the applicable transition period.
Important facts for investors to verify
- Confirm cash runway against actual quarterly operating cash burn, planned clinical spending and lease-related costs.
- Track whether the planned IND submissions occurred on schedule and review resulting clinical data, safety findings and regulatory feedback.
- Verify the terms, timing and collectability of Merck funding, milestone payments and any second-target selection; do not treat maximum potential payments as committed revenue.
- Monitor manufacturing capacity, supplier concentration, and the company’s ability to secure clinical-trial materials.
- Assess share-count dilution, including equity awards and future financing needs, alongside progress toward clinical development.